Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06071767 · ClinicalTrials.gov registry record · Phase 1
Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1
A Phase 1 study of HIV-1-infection, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Recruiting
- Registry status
- Phase 1
- Development phase
- 36
- Enrollment target
- 12
- Study locations
NCT06071767 is a Phase 1 study of HIV-1-infection that is actively recruiting participants, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 36 participants, below the 351-participant average among 71 other HIV-1-infection trials with a reported enrollment target (90% lower). The trial reports 12 study locations across 12 states.
The verdict
NCT06071767, a Phase 1 study of HIV-1-infection, is actively recruiting participants, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 36 participants
- Enrollment target
- 12
- Study locations
Study Summary
The purpose of this study is to evaluate the safety, tolerability, and efficacy of therapeutic vaccination with chimpanzee adenovirus ChAdOx1- and poxvirus modified vaccinia Ankara (MVA)-vectored conserved mosaic T-cell vaccines in a sequential regimen with the toll-like receptor 7 (TLR7) agonist vesatolimod (VES) and two broadly neutralizing antibodies (bNAbs) compared to placebo, to induce HIV-1 control during analytic treatment interruption (ATI).
Conditions Studied
Interventions
- BIOLOGICAL ChAdOx1.tHIVconsv1
- BIOLOGICAL ChAdOx1.HIVconsv62
- BIOLOGICAL MVA.tHIVconsv3
- BIOLOGICAL MVA.tHIVconsv4
- DRUG Vesatolimod (VES)
Study Locations (12)
California
- University of California, San Diego AntiViral Research Center CRS - San Diego
Georgia
- Ponce de Leon Center CRS - Atlanta
Illinois
- Northwestern University CRS - Chicago
Massachusetts
- Massachusetts General Hospital CRS (MGH CRS) - Boston
Missouri
- Washington University Therapeutics CRS - St Louis
New York
- Columbia Physicians & Surgeons CRS - New York
North Carolina
- Chapel Hill CRS - Chapel Hill
Ohio
- Ohio State University CRS - Columbus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2024-04-01 |
| Est. Completion | 2029-08-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06071767
The ClinicalTrials.gov registry entry for NCT06071767 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 351-participant average among 71 other HIV-1-infection trials with a reported enrollment target (90% lower). The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV-1-infection appearing as the primary indexed condition, and to 5 interventions - of which ChAdOx1.tHIVconsv1 is the first listed.
NCT06071767 reports 12 study locations spanning 12 distinct geographic areas - top geographies include California, Georgia, Illinois.
Frequently Asked Questions
What is clinical trial NCT06071767 about?
NCT06071767 is a clinical study titled "Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1". The purpose of this study is to evaluate the safety, tolerability, and efficacy of therapeutic vaccination with chimpanzee adenovirus ChAdOx1- and poxvirus modified vaccinia Ankara (MVA)-vectored conserved mosaic T-cell vaccines in a sequential regimen with the toll-like receptor 7 (TLR7) agonist ve...
What is the current status of trial NCT06071767?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 36 participants. The study started on 2024-04-01. Estimated completion is 2029-08-01.
What conditions does trial NCT06071767 study?
This clinical trial studies the following conditions: HIV-1-infection.
What interventions are being tested in trial NCT06071767?
The interventions under investigation include: ChAdOx1.tHIVconsv1 (BIOLOGICAL), ChAdOx1.HIVconsv62 (BIOLOGICAL), MVA.tHIVconsv3 (BIOLOGICAL), MVA.tHIVconsv4 (BIOLOGICAL), Vesatolimod (VES) (DRUG).
Who is sponsoring clinical trial NCT06071767?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06071767 being conducted?
This trial has 12 study locations across California, Georgia, Illinois, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV-1-infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of GS-3242 in Participants With HIV-1; Substudy-05
RECRUITING · Phase 1
-
Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to HIV
RECRUITING · Phase 1
-
Study of Oral and Long-Acting Injectable Cabotegravir and Rilpivirine in Virologically Suppressed Children Living With HIV-1, Two to Less Than 12 Years of Age
RECRUITING · Phase 1
-
PET Imaging of Radiolabeled Anti-HIV-1 Envelope Monoclonal Antibody (VRC01)
RECRUITING · Phase 1
-
Safety Study of MucoCept-CVN
RECRUITING · Phase 1
-
A Clinical Trial Investigating the Safety and Biological Activity of the Antibody BNT351 in Adults Living Without and With HIV
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.